Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia

* Clinical and genetic factors consistent with High risk : Induction → Consolidation 1. BM MRD \&lt; 0.01% : IM #1 → DI #1 → IM #2 → Maintenance 2. BM MRD ≥ 0.01% : IM #1 → DI #1 → IM #2 → DI #2 → Maintenance 3. BM MRD ≥ 0.01% after Consolidation <!-- --> 1. T cell ALL : Change to very high risk regimen 2. Pre-B ALL : IM #1 → Intensification 1. BM MRD \&lt; 0.01% after IM #1 : DI #1 → IM #2 → DI #2 → Maintenance 2. BM MRD ≥ 0.01% after IM #1 : Change to Very high risk regimen * Difference in the number of \&#39;interim maintenance(IM)\&#39; and \&#39;delayed

Trial Details

NCT ID
NCT06184009
Phase
PHASE2
Sponsor
Jae Wook Lee
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • ALL, High risk
Locations (sample)
  • Seoul, Seoul, South Korea|37.566,126.9784
  • Seoul, Seoul, South Korea|37.566,126.9784
  • Incheon, South Korea|37.45646,126.70515
  • Seoul, South Korea|37.566,126.9784
  • Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

  • Age: 1year\~19years of age at diagnosis
  • Patients who are newly diagnosed Pre-B ALL and meet one of the following criteria
  • High-risk group according to the National Cancer Institute (NCI)/Rome: Age greater than or equal to 10 years and less than 19 years at diagnosis, o…
  • If extra-bone marrow lesions are identified at the time of diagnosis, Central nervous system involvement (CNS3) or testicular involvement

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →